Gottfried E. Konecny, MD

Gottfried Konecny, MD, discusses patient-reported outcomes from the phase 3 MIRASOL trial in platinum-resistant ovarian cancer.

Gottfried Konecny, MD, discusses the MIRASOL trial that evaluated mirvetuximab soravtansine in FRα-positive platinum-resistant recurrent ovarian cancer.

Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer.

Gottfried E. Konecny, MD, discusses the impact of maintenance PARP inhibitors on survival in patients with ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the indications for the FDA-approved PARP inhibitors in recurrent ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses studies that demonstrate the value of PARP inhibitors in the treatment of patients with ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses response to PARP inhibitors in ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses resistance to PARP inhibitors in ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.